Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal bupivacaine single-shot adductor canal block for postoperative analgesia after total knee arthroplasty
ChiCTR2400090405Phase 4Not yet recruiting
- Sponsor
- Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine
- Start
- Sep 2024
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial of liposomal bupivacaine and bupivacaine in postoperative pain (2 arms), sponsored by Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine. Primary endpoints: Area under the curve of NRS pain intensity score within 0-72 hours after surgery and Cumulative opioid consumption within 72 hours after surgery. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
liposomal bupivacainebupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on ChiCTR2400090405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090405.